Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …

Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with
Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug …

Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …

Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and
has become an urgent public health problem in most areas of the world. Substantial …

The deficiency in cholinergic neurotransmission in Alzheimer's disease has led to the
development of cholinesterase inhibitors as the first-line treatment for symptoms of this …

Abstract Objectives Pharmacological treatment of Alzheimer's disease focuses on correcting
the cholinergic deficiency in the central nervous system with cholinesterase inhibitors. Three …

Background: We investigated the effect of cholinesterase inhibitors on all-cause
discontinuation, efficacy and safety, and the effects of study design-, intervention-, and …

Early research into Alzheimer's disease launched the cholinergic hypothesis, based on the
correlation between central cholinergic deficiency and clinical measures of cognitive …

Background** This review is awaiting update with a new protocol. The methods used for the
review were acceptable when the review was published but do not meet contemporary …